Trial Profile
A Randomized, Phase II Study of Apalutamide plus/minus Stereotactic Body Radiotherapy (SBRT) in Castration-Resistant Prostate Cancer Patients With Oligometastatic Disease on PSMA-PET Imaging
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Feb 2024
Price :
$35
*
At a glance
- Drugs Apalutamide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms PILLAR
- 21 Feb 2024 Planned number of patients changed from 60 to 26.
- 21 Feb 2024 Planned End Date changed from 31 Dec 2024 to 31 Jan 2027.
- 21 Feb 2024 Planned primary completion date changed from 31 Dec 2023 to 30 Jun 2025.